MBX

MBX Biosciences develops engineered peptide therapies for endocrine disorders. Its lead prodrug for hypoparathyroidism offers more convenient dosing.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2024
Stage of Initial Investment
Series B
Initial Investment Year
2022